Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
45 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
- D3.114 - Does severe asthma exist in preschool children?
- D3.115 - Outcome and complications of COVID-19 among children with asthma in South Korea: a national incident cohort study
- D3.116 - Mepolizumab as game changer in a case of severe occupational asthma with rhinitis and contact dermatitis
- D3.117 - Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice
- D3.118 - Antibiotic Cocktail-Induced Gut Microbiota Dysbiosis Modulates Gut and Airway Immunity, Attenuating Allergic Airway Inflammation
- D3.119 - Selection of Biologics for Severe Pediatric Asthma with Allergic Eosinophilic Phenotype
- D3.122 - Management Challenges in Pediatric Asthma with Long QT Syndrome
- D3.123 - Dupilumab: Improved Asthma Control and Quality of Life in Pediatric Patients - A Real-World, Single-Center Study
- D3.124 - Severe asthma associated with hereditary angioedema type 1 and other pathologies
- D3.125 - ‘’Save the World-SynAir-G": Evaluation of Internal Reliability of an Innovative Application for Student Health Data Collection
Pagination
Current page
1
Page
2
Page
3
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download